Nang Kuang Pharmaceutical Co Ltd (1752) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Nang Kuang Pharmaceutical Co Ltd stock TWD 35.09, price TWD 29.85, upside +17.6%, quality 64 out of 100. Rating: undervalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 26.97 TWD – 3,837 TWD · fair‑value band 23.29 TWD – 49.65 TWD · the 29.85 TWD price screens below the 35.09 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Nang Kuang Pharmaceutical Co in your weekly email
Every Wednesday you see whether Nang Kuang Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Nang Kuang Pharmaceutical Co., Ltd. manufactures, processes, trades in, imports, and exports pharmaceuticals and medical devices in Taiwan, China, Japan, the United States, and internationally.
Show moreShow less
The company offers ready to use injections, such as prefilled syringe injections and premixed IV infusions; anti-aging and preventive medicines; chemotherapy and oncology products; and non-PVC IV infusion.
It also provides various products in the areas of cardiovascular, gastrointestinal, nervous, musculo-skeletal, and respiratory system, as well as in alimentary and metabolism, blood, antineoplastic and immunomodulatory, dermatological, genito-urinary and sex hormone, systemic hormone and antibacterial, cosmetics, and hospital solutions.
In addition, the company is involved in trading of pharmaceuticals. Nang Kuang Pharmaceutical Co., Ltd. was founded in 1963 and is headquartered in Tainan City, Taiwan.
Stock analysis
Nang Kuang Pharmaceutical Co Ltd (1752) currently trades at 29.85 TWD, while our model-based Fair Value estimate is 35.09 TWD, implying the stock looks roughly 15% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 45.26 TWD per share, and 14 of the 25 models we run sit above the 29.85 TWD price.
Bear case: the Dividend Discount group reads lowest at 9.01 TWD, and 11 of the 25 models stay below the price. Data coverage for this calculation is low.
Scenario range: 23.29 TWD (bear) to 49.65 TWD (bull), the price of 29.85 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Nang Kuang Pharmaceutical Co Ltd reported revenue of 2.2B TWD in FY2025 versus 1.8B TWD in FY2021, a compound +5.0%/yr. Reported net income was 244M TWD in FY2025, compounding +5.6%/yr from FY2021.
Key figures
Market cap 3.0B TWD (≈ $90.9M) Micro · P/E ratio 14.8 · P/S ratio 1.42 · EPS (TTM) 2.02 TWD · Net margin 9.7% · Return on equity 8.5% · Return on assets (EBIT) 8.2% (5-year average) · Operating margin 14.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 18%, 1752 screens cheaper than that median.
Fair Value models
Bear23.29 TWDFair Value 35.09 TWDBull49.65 TWD
Price 29.85 TWD · Upside +17.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.73 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Start year 2020 (pandemic). Over 10 years: +3.6% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+4.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.4.6% vs 2.1%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 14%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +10.7% a year for the price.
Compare Nang Kuang Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Above median
Fair Value upside+17.6% · Above median
Profitability
Return on equity (12 months)8.5% · Above median
Return on assets6.4% · Above median
Net margin (12 months)9.7% · Above median
Operating margin (12 months)14.1% · Above median
Growth and dividend
Revenue growth (quarter YoY)−0.6% · Bottom 25%
Dividend yield (12 months)0.0% · Bottom 25%
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)14.8× · Cheaper than median
P/B1.20× · Cheaper than median
P/S (12 months)1.42× · Cheaper than median
Price / free cash flow (fiscal year)16.3× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Nang Kuang Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1752
Frequently asked questions
Is Nang Kuang Pharmaceutical Co Ltd (1752) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 35.09 TWD versus a price of 29.85 TWD, about +18% upside (undervalued).
What is the fair value of 1752?
Our model-based fair value for Nang Kuang Pharmaceutical Co Ltd is 35.09 TWD (as of Nov 5, 2026), built from audited fundamentals. The current price: 29.85 TWD.
What is the quality score of 1752?
Nang Kuang Pharmaceutical Co Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nang Kuang Pharmaceutical Co Ltd (1752)?
Our model-based price target is the fair value of 35.09 TWD (as of Nov 5, 2026) from 25 valuation models. Cautious scenario 23.29 TWD, optimistic scenario 49.65 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Nang Kuang Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at 35.09 TWD, about +18% upside versus a price of 29.85 TWD (undervalued). Cautious scenario 23.29 TWD, optimistic scenario 49.65 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Nang Kuang Pharmaceutical Co Ltd (1752)?
Nang Kuang Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 2.1B TWD (latest available figure, as of Nov 5, 2026).
What growth is priced into Nang Kuang Pharmaceutical Co Ltd (1752)?
For today's price to be fair in a discounted-cash-flow model, Nang Kuang Pharmaceutical Co Ltd would have to grow free cash flow by +12.5 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.3 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 1752 use?
Our models discount Nang Kuang Pharmaceutical Co Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.13, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Nang Kuang Pharmaceutical Co Ltd that is +12.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Nang Kuang Pharmaceutical Co Ltd (1752) delivered so far?
Over the past 5 years revenue at Nang Kuang Pharmaceutical Co Ltd grew +4.3 % a year. The price currently implies free-cash-flow growth of +12.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Nang Kuang Pharmaceutical Co Ltd (1752) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Nang Kuang Pharmaceutical Co Ltd (+12.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Nang Kuang Pharmaceutical Co Ltd (1752)?
The free-cash-flow yield on the price is 6.13 %: that much free cash flow Nang Kuang Pharmaceutical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Nang Kuang Pharmaceutical Co Ltd (1752)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nang Kuang Pharmaceutical Co Ltd it is 35.09 TWD per share (as of Nov 5, 2026), against a price of 29.85 TWD. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Nang Kuang Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 1752 trades below its calculated fair value: price 29.85 TWD, fair value 35.09 TWD, a gap of about +18% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1752?
No. The price is what the market pays today (29.85 TWD); the fair value is what the company's own numbers justify (35.09 TWD). For Nang Kuang Pharmaceutical Co Ltd the two are 5.24 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Nang Kuang Pharmaceutical Co Ltd worth?
The market values Nang Kuang Pharmaceutical Co Ltd at about 3.0B TWD (market capitalisation, as of Nov 5, 2026). Per share that is 29.85 TWD; our models calculate a fair value of 35.09 TWD per share.
What do the bullish and bearish scenarios say about 1752?
Our models span a range for Nang Kuang Pharmaceutical Co Ltd: cautious scenario 23.29 TWD, base 35.09 TWD, optimistic 49.65 TWD per share (as of Nov 5, 2026, price 29.85 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1752?
Nang Kuang Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 14.8 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 35.09 TWD is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 19.6. Other multiples: P/B 1.2, P/S 1.4, EV/EBITDA 6.4.
How solid is the balance sheet of Nang Kuang Pharmaceutical Co Ltd (1752)?
Balance-sheet figures for Nang Kuang Pharmaceutical Co Ltd (as of Nov 5, 2026): return on equity 8.5%, debt of 0.08 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 1752 from its 52-week high?
Nang Kuang Pharmaceutical Co Ltd trades at 29.85 TWD, about 19% below its 52-week high of 36.74 TWD and 1% above the low of 29.55 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 35.09 TWD is for.
Which stocks are comparable to Nang Kuang Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nang Kuang Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price 29.85 TWD, calculated fair value 35.09 TWD (+18%), Quality Score 64/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1752 calculated?
We run Nang Kuang Pharmaceutical Co Ltd through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 35.09 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Nang Kuang Pharmaceutical Co Ltd currently trades 15% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nang Kuang Pharmaceutical Co Ltd (1752)?
The closing price on Nov 9, 2026 was 29.85 TWD. Our model-based fair value is 35.09 TWD, about +18% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nang Kuang Pharmaceutical Co Ltd right now?
A fairly wide model range (23.29 TWD to 49.65 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Nang Kuang Pharmaceutical Co Ltd (1752) come from?
Earnings per share at Nang Kuang Pharmaceutical Co Ltd grew +3.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.6 %, EBIT margin −0.5 %, tax rate +0.0 %, residual (interest, one-offs) −0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Nang Kuang Pharmaceutical Co Ltd
How large is the market capitalisation of Nang Kuang Pharmaceutical Co Ltd (1752)?
The market capitalisation of Nang Kuang Pharmaceutical Co Ltd is 3.0B TWD (≈ $90.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nang Kuang Pharmaceutical Co Ltd (1752)?
The price-to-sales ratio of Nang Kuang Pharmaceutical Co Ltd is 1.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nang Kuang Pharmaceutical Co Ltd (1752)?
Earnings per share at Nang Kuang Pharmaceutical Co Ltd are 2.02 TWD (price ÷ EPS = P/E 14.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nang Kuang Pharmaceutical Co Ltd (1752)?
The net margin of Nang Kuang Pharmaceutical Co Ltd is 9.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nang Kuang Pharmaceutical Co Ltd (1752)?
The return on equity (ROE) of Nang Kuang Pharmaceutical Co Ltd is 8.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nang Kuang Pharmaceutical Co Ltd (1752)?
On an EBIT basis the return on assets of Nang Kuang Pharmaceutical Co Ltd is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nang Kuang Pharmaceutical Co Ltd (1752)?
The operating margin of Nang Kuang Pharmaceutical Co Ltd is 14.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nang Kuang Pharmaceutical Co Ltd (1752)?
Revenue at Nang Kuang Pharmaceutical Co Ltd is growing −0.6% versus a year earlier (3y avg +3.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nang Kuang Pharmaceutical Co Ltd (1752)?
Earnings per share at Nang Kuang Pharmaceutical Co Ltd are growing +1.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Nang Kuang Pharmaceutical Co Ltd (1752) carry?
The net debt of Nang Kuang Pharmaceutical Co Ltd is 310M TWD (fiscal year 2025, ≈ 1.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Nang Kuang Pharmaceutical Co Ltd in the live analysis
One click puts Nang Kuang Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026